Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Lymphoma

 

Monoclonal Antibody Therapy before STM for Relapsed or Refractory Lymphoid Malignancies (FH 2361)
A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoid Malignancies;    Status: Recruiting;   Study ID: NCT01678443

Rituximab + Lenalidomide vs Chemotherapy (RELEVANCE-7636)
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma. The "RELEVANCE" Trial (Rituximab Lenalidomide Versus Any Chemotherapy)

Investigator: Edward N. Libby, MD;   Conditions: Follicular Lymphoma;    Status: Recruiting;   Study ID: NCT01476787

SGN-35 for CD30-positive Malignancies/Previous SGN-35 study (UW09044)
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study

Investigator: Ajay Gopal, MD ;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT00947856

Brentuximab Vedotin for Relapsed or Refractory CD30+ Lymphoma (FH 7808)
A Pilot Study of Weekly Brentuximab Vedotin in Patients With CD30+ Malignancies Refractory to Every >= 3 Week Brentuximab Vedotin

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01703949

DCDT2980S or DCDS4501A in Combination with MabThera/Rituxan for Relapsed Lymphoma (FH 2649)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination With Rituximab or DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-cell Non Hodgkin's Lymphoma

Investigator: Oliver Press, M.D.;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01691898

Iodine I 131 Monoclonal Antibody BC8 + Autologous SCT for Relapsed Lymphoma (FH-2238)
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies

Investigator: Ajay Gopal, MD;   Conditions: Lymphoma;    Status: Open;   Study ID: NCT00860171

Ofatumumab vs. Rituximab for Relapsed Follicular Lymphoma (FH 2522)
Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Investigator: David Maloney, MD, PhD;   Conditions: Follicular Lymphoma;    Status: Recruiting;   Study ID: NCT01200589

Two Doses of Fostamatinib for Large B-Cell Lymphoma (UW12019)
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Investigator: Andrei R. Shustov, MD;   Conditions: Diffuse Large B-Cell Lymphoma;    Status: Closed;   Study ID: NCT01499303

TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01165112

PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies

Investigator: Vivian Oehler, M.D,;   Conditions: Hematologic Malignancies;    Status: Closed;   Study ID: NCT00953758

LDK378 for Tumors with ALK Mutation (UW10038)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Investigator: Laura Chow, MD;   Conditions: Tumors Characterized by Genetic Abnormalities of ALK;    Status: Closed;   Study ID: NCT01283516

SGN-75 for Lymphoma or Renal Cell Carcinoma (SGN75-001)
A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma

Investigator: John Thompson, MD ;   Conditions: Renal Cell Carcinoma, Non-Hodgkin Lymphoma;    Status: Closed;   Study ID: NCT01015911

Pralatrexate + Chemotherapy for Non-Hodgkin's Lymphoma (FH 7860)
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Investigator: Andrei R. Shustov, MD;   Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma;    Status: Pending;   Study ID: NCT01336933

Zevalin for Newly Diagnosed Diffuse Large B-cell Lymphoma (FH 7779)
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy (SPI-ZEV-11-301)

Investigator: Ajay K. Gopal, MD;   Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma;    Status: Closed;   Study ID: NCT01510184

Combination Chemotherapy + G-CSF + Plerixafor for Lymphoma Patients Undergoing Mobilization of Autologous PBSC (FH 2310)
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor

Investigator: Leona Holmberg, MD, PhD;   Conditions: Non-Hodgkin's Lymphoma;    Status: Closed;   Study ID: NCT01097057

Radiolabeled Monoclonal Antibody and Chemotherapy Before Stem Cell Transplant for High-Risk Lymphoid Malignancies (2728)
A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies

Investigator: Ajay Gopal, MD;   Conditions: Acute Lymphoid Leukemia (ALL); , Burkitt's Lymphoma; , Hodgkin's Lymphoma; , Leukemia; Lymphoma; , Non-Hodgkin's Lymphoma (NHL); , Mycosis Fungoides/Sezary Syndrome;    Status: Recruiting;   Study ID: NCT01921387

Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma (2639)
Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

Investigator: David Maloney, MD, PhD;   Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia;    Status: Recruiting;   Study ID: NCT01865617

GA101 for non-Hodgkin's Lymphoma (2388)
An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + GA101, a monoclonal anti-CD20 antibody (also known as obinutuzumab or RO5072759), in patients with rituximab-refractory, indolent non-Hodgkin's lymphoma

Investigator: Oliver Press, MD, PhD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01059630

KW-0761 (Mogamulizumab ) vs. Vorinostat for Relapsed/Refractory CTCL (20121464)
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell LymphomaOpen-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Investigator: Andrei Shustov, MD;   Conditions: Cutaneous T-Cell Lymphoma;    Status: Recruiting;   Study ID: NCT01728805

SGN-35 for Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma - Expanded Access (20100989)
A Treatment-Option Study of Brentuximab Vedotin (SGN-35) in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Investigator: Andrei Shustov, MD;   Conditions: Hodgkin's LymphomaAnaplastic Large-Cell Lymphoma;    Status: Closed;   Study ID: NCT01196208

Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid for Relapsed or Refractory T-cell Lymphoma (6774)
A Phase I, Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma

Investigator: Andrei Shustov, MD;   Conditions: Cutaneous T-Cell Lymphoma;    Status: Closed;   Study ID: NCT00554827

Chemo Based on PET Scan for Stage I-II Hodgkin Lymphoma (CTSU C50604)
Phase II Trial Of Response-Adapted Chemotherapy Based On Positron Emission Tomography For Non-Bulky Stage I And II Hodgkin Lymphoma

Investigator: Fred Appelbaum, MD;   Conditions: Hodgkin's Lymphoma;    Status: Closed;   Study ID: NCT01132807

Y-90-Ibritumomab Tiuxetan + Reduced-Intensity Allogeneic Transplant for Aggressive B-Cell Lymphoma (FH 2398)
A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma

Investigator: Ajay Gopal, MD;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01434472

P276-00 for Relapsed and/or Refractory Mantle Cell Lymphoma (UW09052)
Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma

Investigator: Ajay Gopal, MD;   Conditions: Mantle Cell Lymphoma;    Status: Closed;   Study ID: NCT00843050

Brentuximab Vedotin for Non-Hodgkin Lymphoma (UW11026)
A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)

Investigator: Andrei Shustov, MD;   Conditions: Non-Hodgkin's Lymphoma;    Status: Recruiting;   Study ID: NCT01421667

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

Vorinostat and Combination Chemotherapy With Rituximab for HIV-Related Lymphoma (FH 2483)
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma

Investigator: Ann Woolfrey, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01193842

Bortezomib and Vorinostat Post ASCT for Non-Hodgkin Lymphoma (FH 2292)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen

Investigator: Leona A. Holmberg, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT00992446

Ofatumumab and Bortezomib for Waldenstrom Macroglobulinemia (FH 7574)
A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia

Investigator: Pamela S. Becker, MD;   Conditions: Waldenstrom Macroglobulinemia;    Status: Pending;   Study ID: NCT01536067

A+AVD vs. ABVD as Frontline Therapy for Hodgkin Lymphoma (UW12044)
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: Hodgkin Lymphoma;    Status: Recruiting;   Study ID: NCT01712490

Bortezomib + Rituximab for Mantle Cell Lymphoma Post Stem Cell Transplant (FH 2620)
A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation

Investigator: Leona A. Holmberg, MD, PhD;   Conditions: Mantle Cell Lymphoma;    Status: Pending;   Study ID: NCT01267812

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma in Younger Patients (AHOD1221)
A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma

Investigator: Rebecca H. Johnson, MD;   Conditions: Hodgkin Lymphoma;    Status: Recruiting;   Study ID: NCT01780662

PCI-32765 (Ibrutinib) + R-CHOP for Newly Diagnosed Large B-Cell Lymphoma (UW13027)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01855750

GDC-0853 Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (UW13044)
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Investigator: Stephen Douglas Smith, MD;   Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01991184

Ibrutinib for Relapsed/Refractory Marginal Zone Lymphoma (UW13052)
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Investigator: ;   Conditions: Marginal Zone Lymphoma, B-cell Lymphoma;    Status: Recruiting;   Study ID: NCT01980628

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

BMS-986016 for Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Investigator: Ajay K. Gopal, MD;   Conditions: Hematologic Neoplasms;    Status: Pending;   Study ID: NCT02061761

IMO-8400 for Relapsed or Refractory Waldenstrom's Macroglobulinemia (UW14016)
Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Investigator: Edward N. Libby, MD;   Conditions: Waldenstrom's Macroglobulinemia;    Status: Recruiting;   Study ID: NCT02092909

GS-9973 for Relapsed or Refractory Hematologic Malignancies (UW13029)
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Investigator: Andrei R. Shustov, MD;   Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma;    Status: Recruiting;   Study ID: NCT01799889

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide for Previously Untreated Mantle Cell Lymphoma (E1411)
Intergroup Randomized Phase 2 Four Arm Study In Patients = 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ? R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV? R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ? LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ? LR)

Investigator: Brian Till, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01415752

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) (9111)
A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Investigator: Ajay K. Gopal, MD;   Conditions: Hodgkin Lymphoma;    Status: Pending;   Study ID: NCT02227199

Ibrutinib for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (9107)
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: B-Cell Non-Hodgkin Lymphoma;    Status: Pending;   Study ID: NCT02207062

Romidepsin for Maintenance Therapy Post Transplant for T-Cell Non-Hodgkin Lymphoma (9023)
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Investigator: Andrei R. Shustov, MD;   Conditions: T Cell Non-Hodgkin Lymphoma;    Status: Pending;   Study ID: NCT01908777